Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Capital Leases: 2017-2025

Historic Capital Leases for Organogenesis Holdings (ORGO) over the last 6 years, with Sep 2025 value amounting to $2.1 million.

  • Organogenesis Holdings' Capital Leases rose 105.50% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 105.50%. This contributed to the annual value of $718,000 for FY2024, which is 61.97% down from last year.
  • As of Q3 2025, Organogenesis Holdings' Capital Leases stood at $2.1 million, which was up 2,036.73% from $98,000 recorded in Q2 2025.
  • Organogenesis Holdings' 5-year Capital Leases high stood at $10.5 million for Q1 2021, and its period low was $98,000 during Q2 2025.
  • Moreover, its 3-year median value for Capital Leases was $1.2 million (2024), whereas its average is $1.2 million.
  • In the last 5 years, Organogenesis Holdings' Capital Leases slumped by 93.21% in 2021 and then surged by 226.87% in 2024.
  • Organogenesis Holdings' Capital Leases (Quarterly) stood at $831,000 in 2021, then reached $1.9 million in 2023, then tumbled by 61.97% to $718,000 in 2024, then skyrocketed by 105.50% to $2.1 million in 2025.
  • Its Capital Leases was $2.1 million in Q3 2025, compared to $98,000 in Q2 2025 and $411,000 in Q1 2025.